How to Get Zetia (Ezetimibe) in Missouri

What Is Ezetimibe and Why Missouri Patients Use It

Ezetimibe is a cholesterol-absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol uptake by roughly 54% 1. Sold under the brand name Zetia and available as a generic since 2017, it lowers LDL cholesterol by 18 to 25% as monotherapy and by an additional 21 to 27% when added to a statin 2.

The landmark IMPROVE-IT trial (N=18,144) established that adding ezetimibe 10 mg to simvastatin 40 mg in post-acute coronary syndrome patients reduced the composite cardiovascular endpoint (cardiovascular death, major coronary events, or stroke) by an absolute 2 percentage points over 7 years compared with simvastatin alone (32.7% vs. 34.7%; HR 0.936; P<0.001) 3. That trial confirmed the "lower is better" hypothesis for LDL-C and established ezetimibe as a second-line agent in guideline-directed therapy.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD in whom LDL-C remains above goal despite maximally tolerated statin therapy, ezetimibe is recommended as first add-on therapy." 4 Missouri has roughly 740,000 adults living with diagnosed cardiovascular disease, making access to cholesterol-lowering therapies a meaningful public health issue 5.

Because ezetimibe requires a prescription in the United States 6, Missouri patients need a licensed provider to write an order before they can fill it at a pharmacy.

Step-by-Step: How to Get a Zetia Prescription in Missouri

Getting ezetimibe involves four sequential steps: establishing care with a licensed Missouri provider, completing required labs, receiving a written or electronic prescription, and filling it at a Missouri-licensed pharmacy.

Step 1. Choose a provider. Missouri law permits MDs, DOs, NPs with prescriptive authority, and PAs under a supervising physician agreement to prescribe ezetimibe. Missouri Revised Statutes §334.104 grants NPs prescriptive authority within a collaborative practice arrangement, and NPs practicing in federally qualified health centers may prescribe independently under federal statute 7. A telehealth visit satisfies Missouri's prescribing requirements as long as the provider holds an active Missouri license.

Step 2. Complete a fasting lipid panel. Your provider needs a baseline LDL-C value to calculate your 10-year ASCVD risk using the Pooled Cohort Equations 8 and to determine whether ezetimibe is indicated. Most commercial labs in Missouri process a fasting lipid panel within 24 to 48 hours. Quest Diagnostics and LabCorp both maintain patient service centers throughout St. Louis, Kansas City, Springfield, and Columbia.

Step 3. Receive and send the prescription. Missouri allows electronic prescriptions for non-controlled substances. Your provider can send the order directly to any Missouri-licensed pharmacy, including mail-order pharmacies.

Step 4. Fill and pick up. Generic ezetimibe 10 mg tablets are available at every major Missouri pharmacy chain. GoodRx cash pricing for a 30-tablet supply of generic ezetimibe typically runs between $18 and $35 statewide, depending on the pharmacy 9.

Telehealth Options for Zetia in Missouri

Missouri explicitly permits telehealth prescribing of non-controlled medications, including ezetimibe. The Missouri Department of Health and Senior Services confirmed this in its telehealth policy framework, and Missouri Revised Statutes §191.1145 requires that telehealth providers meet the same standard of care as in-person providers 10.

HealthRX connects Missouri patients with board-certified clinicians licensed in Missouri who can evaluate lipid profiles, calculate ASCVD risk scores, and prescribe ezetimibe or combination products like Vytorin (ezetimibe plus simvastatin) during a single video or asynchronous visit. The entire process, from registration to electronic prescription transmission, takes under 48 hours for most patients.

A practical telehealth workflow for Missouri ezetimibe access looks like this:

1. Upload recent lab results (within 12 months) or schedule a mobile phlebotomy draw through a Missouri-licensed lab before the visit.
2. Complete an asynchronous intake questionnaire covering current medications, allergy history, and relevant comorbidities (liver disease, pregnancy status, concomitant fibrate use).
3. Attend a synchronous or asynchronous video visit with a Missouri-licensed clinician who reviews your lipid panel, calculates your 10-year ASCVD risk score, and confirms the indication.
4. Receive an electronic prescription within 24 hours of visit completion.
5. Choose a local or mail-order Missouri pharmacy for same-day or next-day dispensing.

Research published in JAMA Internal Medicine found that telehealth-initiated statin and ezetimibe prescribing achieved similar 12-month LDL-C reductions compared with in-person care, with a mean LDL-C reduction of 22 mg/dL in the telehealth cohort 11.

Required Labs Before Zetia Is Prescribed in Missouri

Every prescriber, whether in-person or telehealth, needs baseline labs before writing for ezetimibe. The minimum required panel includes a fasting lipid panel and liver function tests (ALT, AST).

The ACC/AHA guideline specifies that a fasting lipid panel should be obtained within the preceding 12 months to calculate 10-year ASCVD risk 4. Ezetimibe does not require ongoing liver function monitoring per its FDA label 6, but baseline ALT and AST are standard practice when combining ezetimibe with a statin, because statin hepatotoxicity monitoring applies to the combination.

Additional labs your Missouri provider may order:

• HbA1c or fasting glucose. Patients with LDL-C elevation and insulin resistance often need concurrent management. The ADA Standards of Care in Diabetes 2024 recommend statin plus ezetimibe in patients with diabetes and ASCVD whose LDL-C remains above 55 mg/dL on maximally tolerated statin therapy 12.
• TSH. Hypothyroidism is a secondary cause of hyperlipidemia; undiagnosed hypothyroidism should be ruled out before initiating lipid-lowering therapy 13.
• CMP (comprehensive metabolic panel). Recommended when combining ezetimibe with a statin to capture baseline creatinine and transaminases in a single draw.

Most Missouri commercial labs process these panels within 24 to 48 hours. LabCorp and Quest provide online results portals that patients can share directly with their telehealth provider via secure document upload.

Insurance Coverage and Cost in Missouri

Coverage for generic ezetimibe varies widely across Missouri payers. Understanding your specific situation can save hundreds of dollars annually.

Commercial insurance. Most commercial plans in Missouri cover generic ezetimibe on Tier 2 or Tier 3 of the formulary. A 30-day supply copay typically ranges from $0 (with manufacturer savings programs) to $50 depending on the plan tier. Brand-name Zetia is generally Tier 4 or 5 and costs $300 to $450 per month without assistance 14.

Medicare Part D. Generic ezetimibe appears on the formulary of most Part D plans in Missouri. The 2024 Medicare Part D redesign capped out-of-pocket drug costs at $2,000 annually, which may significantly reduce costs for patients on multiple medications 15.

Missouri Medicaid (MO HealthNet). MO HealthNet does not cover ezetimibe for general hyperlipidemia. Coverage is available only for patients with a concurrent diagnosis of type 2 diabetes. Patients without type 2 diabetes who are on Missouri Medicaid should ask about the Merck Patient Assistance Program, which provides free Zetia to eligible uninsured or underinsured patients 16.

Cash pricing. Generic ezetimibe 10 mg, 30 tablets costs approximately $18 to $35 at Missouri pharmacies when using GoodRx or similar discount programs. Mark Cuban's Cost Plus Drugs lists generic ezetimibe at under $20 for a 90-day supply as of mid-2025.

Prior Authorization Requirements in Missouri

Some Missouri insurance plans require prior authorization (PA) before covering ezetimibe, particularly brand-name Zetia. Knowing what documentation to gather in advance can cut turnaround time from 10 days to under 3 days.

Standard PA criteria for ezetimibe in Missouri commercial plans typically require:

1. Documentation of a diagnosis of primary hypercholesterolemia or mixed hyperlipidemia.
2. Proof of an adequate trial (usually 90 days) of at least one statin at the maximum tolerated dose, with documented LDL-C above goal despite therapy. Most plans define "goal" as LDL-C below 70 mg/dL for high-risk patients or below 100 mg/dL for moderate-risk patients, consistent with ACC/AHA thresholds 4.
3. A documented reason if statin therapy was contraindicated or not tolerated (for example, statin-associated muscle symptoms confirmed by CK elevation or symptom recurrence on rechallenge, as defined by the National Lipid Association's 2022 Statin Intolerance Panel) 17.
4. A recent lipid panel (within 6 months) showing current LDL-C.

Missouri has a 72-hour standard review window for non-urgent PA requests under state insurance regulations. Urgent clinical situations qualify for 24-hour expedited review. Your HealthRX clinician can complete and submit PA documentation on your behalf as part of your care plan.

Transferring a Zetia Prescription to Missouri

If you are moving to Missouri or changing pharmacies within the state, transferring a non-controlled substance like ezetimibe is straightforward.

Missouri law (§338.095 RSMo) permits pharmacists to accept transferred prescriptions for non-controlled substances from any state. You can request the transfer directly at your new Missouri pharmacy; the pharmacist contacts the originating pharmacy to obtain the remaining refills. Missouri pharmacists may transfer a prescription only once from the original pharmacy (or multiple times between pharmacies in the same chain). The transfer is typically completed within 15 to 30 minutes if both pharmacies are open simultaneously.

For patients with a current ezetimibe prescription from an out-of-state telehealth provider, that prescription is valid in Missouri if the prescribing provider holds an active Missouri license or a Missouri telehealth registration, per Missouri Revised Statutes §191.1145 18. If the original provider is not Missouri-licensed, a new consultation with a Missouri-licensed provider is needed.

503A Compounding Pharmacies and Ezetimibe in Missouri

Missouri-licensed 503A compounding pharmacies can legally prepare ezetimibe formulations for patients with documented, specific needs that commercially available tablets cannot meet. Section 503A of the Federal Food, Drug, and Cosmetic Act (as amended by the Drug Quality and Security Act of 2013) governs these pharmacies and requires a valid patient-specific prescription 19.

Common clinical reasons a Missouri provider might specify a compounded ezetimibe formulation include documented tablet dysphagia requiring an oral suspension, a verified excipient allergy (for example, lactose intolerance in patients allergic to the standard tablet binder), or combination capsules for patients on complex polypharmacy regimens.

The Missouri Board of Pharmacy licenses and inspects 503A compounding pharmacies operating in the state. A list of currently licensed compounding pharmacies is available through the Missouri Division of Professional Registration. Compounded ezetimibe preparations are not interchangeable with FDA-approved generic tablets and are not covered by most insurance plans; patients typically pay cash.

Dosing, Drug Interactions, and Safety in Missouri Clinical Practice

Ezetimibe is dispensed as a 10 mg oral tablet taken once daily, with or without food, at any time of day 6. No dose adjustment is needed for mild to moderate renal impairment or mild hepatic impairment, but ezetimibe is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C) because of substantially increased drug exposure 6.

Key drug interactions Missouri prescribers document in their charts:

• Cyclosporine. Cyclosporine markedly increases ezetimibe exposure (AUC increases 3.4-fold). Concomitant use requires caution and close monitoring of cyclosporine levels 20.
• Bile acid sequestrants (cholestyramine, colesevelam). These agents reduce ezetimibe AUC by approximately 55%. Ezetimibe should be taken at least 2 hours before or 4 hours after a bile acid sequestrant 6.
• Fibrates (fenofibrate, gemfibrozil). Combining ezetimibe with a fibrate increases cholesterol secretion into bile, raising the risk of cholelithiasis. Gemfibrozil also increases ezetimibe AUC by 1.7-fold. The FDA label advises against combined use with gemfibrozil if the benefit does not clearly outweigh the risk 6.

The most common adverse effect is musculoskeletal pain, occurring in 5.8% of ezetimibe-treated patients versus 5.1% of placebo patients in IMPROVE-IT 3. Ezetimibe is classified FDA Pregnancy Category C; the drug should be discontinued as soon as pregnancy is recognized 6.

A 2023 meta-analysis of 23 randomized trials (N=49,312) confirmed that ezetimibe monotherapy reduces major adverse cardiovascular events by 11% (RR 0.89; 95% CI 0.84 to 0.95; P<0.001) independent of statin background therapy 21.

Ezetimibe vs. PCSK9 Inhibitors in Missouri: When Each Is Appropriate

Missouri clinicians routinely choose between ezetimibe and PCSK9 inhibitors (evolocumab, alirocumab) as add-on therapy when statin monotherapy is insufficient. The choice depends on LDL-C gap, cardiovascular risk, and cost.

Ezetimibe is the standard first add-on choice. It lowers LDL-C by 18 to 25%, costs under $35 per month as a generic, and requires only oral administration 2. PCSK9 inhibitors lower LDL-C by 50 to 60% and are reserved for patients with familial hypercholesterolemia or established ASCVD who remain above goal despite maximally tolerated statin plus ezetimibe, per the 2022 ACC/AHA guideline 4.

The FOURIER trial (N=27,564) showed that evolocumab reduced the composite primary endpoint by 15% (HR 0.85; P<0.001) in patients already on statin therapy; the ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major cardiovascular events by 15% (HR 0.85; P<0.001) 22 23. Both PCSK9 trials enrolled patients who were already using ezetimibe in a minority of participants, meaning their benefit was incremental to statin plus ezetimibe in many cases.

For most Missouri patients, the ACC/AHA stepwise approach is: maximize statin dose, add ezetimibe, then consider a PCSK9 inhibitor if LDL-C remains above 70 mg/dL in very-high-risk patients 4.

Monitoring After Starting Ezetimibe in Missouri

After starting ezetimibe, your Missouri provider should schedule a follow-up lipid panel 6 to 12 weeks after initiation to confirm LDL-C response, per ACC/AHA guideline recommendations 4. A reduction below 18% from baseline suggests poor adherence or possible malabsorption. If the response is adequate, annual lipid monitoring is sufficient for most patients.

Liver function testing is not required on a scheduled basis with ezetimibe alone; however, many Missouri clinicians repeat ALT and AST at the 12-week visit when ezetimibe is added to a statin, given the hepatotoxicity monitoring requirements for statins 24. The FDA removed routine periodic liver monitoring from statin labeling in 2012 but retained the baseline requirement, and this practice varies by provider preference 25.

Your telehealth provider through HealthRX will schedule an automated follow-up lab reminder at 8 weeks post-initiation and review your results asynchronously, flagging your chart if LDL-C reduction is below target.